Glenmark Gets USFDA Approval for Generic Seizure Drug
By Rediff Money Desk, New Delhi Jul 18, 2024 14:21
Glenmark Pharmaceuticals receives USFDA approval to market generic Topiramate Capsules, a medication used for treating and preventing seizures. The drug will be distributed in the US by Glenmark Pharmaceuticals Inc., USA.
![Glenmark Gets USFDA Approval for Generic Seizure Drug](https://im.rediff.com/money/2012/oct/28drug.jpg)
New Delhi, Jul 18 (PTI) Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a medication used to treat and prevent seizures.
The company has received approval from the US Food and Drug Administration (USFDA) for Topiramate Capsules USP in 15 mg and 25 mg strengths, the Mumbai-based drug maker said in a statement.
The company's product is therapeutically equivalent to Janssen Pharmaceuticals Inc's Topamax Capsules (15 mg and 25 mg), it added.
Glenmark said the drug will be distributed in the US market by Glenmark Pharmaceuticals Inc, USA.
According to IQVIA sales data for the 12-month period ending May 2024, the Topamax capsules (15 mg and 25 mg) achieved annual sales of around USD 21.9 million.
Glenmark's current portfolio consists of 198 products authorised for distribution in the US marketplace.
The company said 50 abbreviated new drug applications (ANDAs) are currently pending for approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 0.88 per cent up at Rs 1,422.85 apiece on the BSE.
The company has received approval from the US Food and Drug Administration (USFDA) for Topiramate Capsules USP in 15 mg and 25 mg strengths, the Mumbai-based drug maker said in a statement.
The company's product is therapeutically equivalent to Janssen Pharmaceuticals Inc's Topamax Capsules (15 mg and 25 mg), it added.
Glenmark said the drug will be distributed in the US market by Glenmark Pharmaceuticals Inc, USA.
According to IQVIA sales data for the 12-month period ending May 2024, the Topamax capsules (15 mg and 25 mg) achieved annual sales of around USD 21.9 million.
Glenmark's current portfolio consists of 198 products authorised for distribution in the US marketplace.
The company said 50 abbreviated new drug applications (ANDAs) are currently pending for approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 0.88 per cent up at Rs 1,422.85 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- IFL Enterprises
- 1.36 (+ 4.62)
- 139837616
- Franklin Industries
- 3.90 (+ 4.56)
- 41704768
- Vodafone Idea L
- 16.28 ( -3.04)
- 37101580
- Sawaca Business Mach
- 0.67 ( -4.29)
- 36642255
- Tata Teleservices (M
- 97.43 (+ 19.80)
- 21113173
MORE NEWS
![Sensex Hits...](https://im.rediff.com/80-80/money/2024/jun/26june-bse.jpg)
Sensex Hits 81,000, Nifty at Record 24,800: IT...
The Indian stock market continued its record-breaking run, with Sensex crossing 81,000...
![World's Largest...](https://im.rediff.com/80-80/money/2022/may/30coal3.jpg)
World's Largest Coal Mines: India's SECL Holds...
Two coal blocks in India's South Eastern Coalfields (SECL) rank among the world's 10...
![Infosys Q1 Profit...](https://im.rediff.com/80-80/money/2022/jun/01salil-parekh-1.jpg)
Infosys Q1 Profit Up 7.1%, Raises FY25 Outlook...
Infosys reported a 7% rise in Q1 net profit and raised its FY25 revenue growth guidance...